OCUVEX THERAP
PharmaOCUVEX THERAP is a pharmaceutical company focused on Cardiovascular, Ophthalmology. Key products include OMLONTI.
FDA Novel Drug Designations
(2022)See 1 novel approval →
OCUVEX THERAP's Key Drugs
OCUVEX THERAP's core commercial portfolio centers on OMLONTI, spanning Cardiovascular and Ophthalmology — its most strategically important drugs approved in the last 15 years.
OCUVEX THERAP's Recent FDA Approvals
New NDA/BLA approvals for OCUVEX THERAP over the last two years — novel drugs only, excluding generics and label supplements.
OCUVEX THERAP's Therapeutic Areas
OCUVEX THERAP's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Ophthalmology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
OCUVEX THERAP's Top Competitors
OCUVEX THERAP's closest competitors by therapeutic-area and drug-target overlap include Novartis, Bayer, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
OCUVEX THERAP Pipeline Snapshot
Active clinical trials for OCUVEX THERAP across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OMLONTI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2022-09-22
- Latest
- 2022-09-22
- Applications
- 1